GNF-5 structure
|
Common Name | GNF-5 | ||
---|---|---|---|---|
CAS Number | 778277-15-9 | Molecular Weight | 418.369 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 612.4±55.0 °C at 760 mmHg | |
Molecular Formula | C20H17F3N4O3 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 324.2±31.5 °C | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of GNF-5GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).IC50 Value: 0.22±0.1 uM (Wild type Abl) [1]Target: Abl GNF-5 is a cell-permeable GNF-2 N-hydroxyethyl carboxamide analog that exhibits in vivo efficacy in suppressing the proliferation of Bcr-abl-expressing Ba/F3 (93% and 83% of no-treatment control, respectively, on days 5 and 7 post treatment; 100 mg/kg b.i.d.) and bone marrow cells (~75% of no-treatment control in both WBC counts and spleen weight on day 7 post treatment; 50 mg/kg b.i.d.) in murine xenograft models of leukemia. Similar to GNF-2, GNF-5 exerts its effect via an allosteric mechanism (IC50 = 0.22 M against wild-type Abl) by targeting the myristate-binding pocket near the c-terminus of Abl kinase domain and thereby altering the conformational dynamics of the ATP-binding pocket. GNF-5 is ineffective toward the myristate-binding site mutant E505K and the ATP-binding site 'gatekeeper' mutant T315I. |
Name | N-(2-hydroxyethyl)-3-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide |
---|---|
Synonym | More Synonyms |
Description | GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).IC50 Value: 0.22±0.1 uM (Wild type Abl) [1]Target: Abl GNF-5 is a cell-permeable GNF-2 N-hydroxyethyl carboxamide analog that exhibits in vivo efficacy in suppressing the proliferation of Bcr-abl-expressing Ba/F3 (93% and 83% of no-treatment control, respectively, on days 5 and 7 post treatment; 100 mg/kg b.i.d.) and bone marrow cells (~75% of no-treatment control in both WBC counts and spleen weight on day 7 post treatment; 50 mg/kg b.i.d.) in murine xenograft models of leukemia. Similar to GNF-2, GNF-5 exerts its effect via an allosteric mechanism (IC50 = 0.22 M against wild-type Abl) by targeting the myristate-binding pocket near the c-terminus of Abl kinase domain and thereby altering the conformational dynamics of the ATP-binding pocket. GNF-5 is ineffective toward the myristate-binding site mutant E505K and the ATP-binding site 'gatekeeper' mutant T315I. |
---|---|
Related Catalog | |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 612.4±55.0 °C at 760 mmHg |
Molecular Formula | C20H17F3N4O3 |
Molecular Weight | 418.369 |
Flash Point | 324.2±31.5 °C |
Exact Mass | 418.125275 |
PSA | 99.86000 |
LogP | 3.31 |
Appearance of Characters | white to beige |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.600 |
Storage condition | 2-8°C |
Water Solubility | DMSO: soluble10mg/mL (clear solution) |
~79% GNF-5 CAS#:778277-15-9 |
Literature: Deng, Xianming; Okram, Barun; Ding, Qiang; Zhang, Jianming; Choi, Yongmun; Adrian, Francisco J.; Wojciechowski, Amy; Zhang, Guobao; Che, Jianwei; Bursulaya, Badry; Cowan-Jacob, Sandra W.; Rummel, Gabriele; Sim, Taebo; Gray, Nathanael S. Journal of Medicinal Chemistry, 2010 , vol. 53, # 19 p. 6934 - 6946 |
Precursor 2 | |
---|---|
DownStream 0 |
HS Code | 2933599090 |
---|---|
Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Benzamide,N-(2-hydroxyethyl)-3-(6-((4-(trifluoromethoxy)phenyl)amino)-4-pyrimidinyl) |
QC-4300 |
Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- |
N-(2-hydroxyethyl)-3-(6-(4-(trifluoromethoxy)phenylamino)pyrimidin-4-yl)benzamide |
GNF-5 |
N-(2-Hydroxyethyl)-3-(6-{[4-(trifluoromethoxy)phenyl]amino}-4-pyrimidinyl)benzamide |
UNII-3ZUA56XMQQ |